CNP Conjugate Sustained Release for Achondroplasia

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current CNP therapies for achondroplasia, such as vosoritide, have limitations due to rapid clearance and degradation, leading to transient hypotensive effects and requiring frequent administration.

Innovation Solution

A unit dosage form comprising a therapeutically effective amount of a CNP conjugate or pharmaceutically acceptable salt, where the CNP moiety is reversibly conjugated to a polymeric moiety, aiming to improve pharmacological window and reduce hypotensive potential.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If native CNP is administered to treat achondroplasia, then growth promotion effect is achieved, but rapid clearance and degradation occur leading to short half-life

Engineering Contradiction:

Improvegrowth promotion effectVSAvoidhalf-life

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent introduces a polymeric moiety as an intermediary carrier that binds to CNP, protecting it from degradation by neutral endopeptidase and extending its half-life in circulation. This intermediary polymer-CNP conjugate serves as a reservoir that releases CNP slowly, maintaining therapeutic levels without rapid clearance.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates a composite molecular structure combining CNP with a polymeric moiety through reversible conjugation. This composite conjugate exhibits enhanced pharmacokinetic properties including extended half-life and reduced degradation, while maintaining the biological activity of CNP for growth promotion.

Inventive Principle:

Principle #40Composite materials

2Reliability

If CNP is administered at supraphysiological levels to normalize dwarfism, then therapeutic efficacy is improved, but transient hypotensive effects increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidhypotensive effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The reversible conjugation of CNP to polymer creates a controlled release system that provides periodic or sustained exposure rather than acute peaks. The polymer-CNP conjugate gradually releases CNP over time, maintaining therapeutic levels without sudden spikes that cause hypotension.

Inventive Principle:

Principle #19Periodic action

Solution Approach 2:

The patent changes the pharmacokinetic parameters of CNP by conjugating it to a polymer, which alters its clearance rate, half-life, and concentration-time profile. This parameter modification allows achieving therapeutic efficacy at lower peak concentrations, reducing hypotensive risk while maintaining growth promotion effect.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If frequent administration of CNP is performed to maintain therapeutic levels, then therapeutic effect is sustained, but treatment complexity and burden increase

Engineering Contradiction:

Improvetherapeutic level maintenanceVSAvoidadministration frequency

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The polymeric moiety performs a preliminary action by binding to CNP before administration, creating a reservoir that releases CNP gradually. This preliminary conjugation step eliminates the need for frequent dosing, as the polymer-CNP complex maintains therapeutic levels over extended periods through controlled degradation and release.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250032585A1Effective Doses of CNP Conjugates

Publication Date: 2025.01.30 ASCENDIS PHARMA GROWTH DISORDERS AS

AI summary

The present invention relates to unit dosage forms comprising a CNP conjugate or pharmaceutically acceptable salt thereof.